These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24102757)

  • 1. Impact of coffee on liver diseases: a systematic review.
    Saab S; Mallam D; Cox GA; Tong MJ
    Liver Int; 2014 Apr; 34(4):495-504. PubMed ID: 24102757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?
    Chen S; Teoh NC; Chitturi S; Farrell GC
    J Gastroenterol Hepatol; 2014 Mar; 29(3):435-41. PubMed ID: 24199670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers.
    Tanaka K; Tokunaga S; Kono S; Tokudome S; Akamatsu T; Moriyama T; Zakouji H
    Int J Epidemiol; 1998 Jun; 27(3):438-43. PubMed ID: 9698132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coffee can be beneficial for patients with liver diseases].
    Kjærgaard M; Thiele M; Krag A
    Ugeskr Laeger; 2014 Oct; 176(43):. PubMed ID: 25353679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coffee and liver diseases.
    Muriel P; Arauz J
    Fitoterapia; 2010 Jul; 81(5):297-305. PubMed ID: 19825397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.
    Kennedy OJ; Roderick P; Buchanan R; Fallowfield JA; Hayes PC; Parkes J
    BMJ Open; 2017 May; 7(5):e013739. PubMed ID: 28490552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coffee and liver health.
    Morisco F; Lembo V; Mazzone G; Camera S; Caporaso N
    J Clin Gastroenterol; 2014; 48 Suppl 1():S87-90. PubMed ID: 25291138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
    Kumada H
    Oncology; 2002; 62 Suppl 1():94-100. PubMed ID: 11868794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coffee Consumption and the Progression of NAFLD: A Systematic Review.
    Sewter R; Heaney S; Patterson A
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coffee and nonalcoholic fatty liver disease: A review.
    Nikrandt G; Chmurzynska A
    Acta Sci Pol Technol Aliment; 2020; 19(3):245-254. PubMed ID: 32978907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Coffee as hepatoprotective factor].
    Szántová M; Ďurkovičová Z
    Vnitr Lek; 2016; 62(12):990-997. PubMed ID: 28139128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis.
    Bravi F; Bosetti C; Tavani A; Gallus S; La Vecchia C
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1413-1421.e1. PubMed ID: 23660416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study.
    Leung WW; Ho SC; Chan HL; Wong V; Yeo W; Mok TS
    J Epidemiol Community Health; 2011 Jun; 65(6):556-8. PubMed ID: 20693491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coffee has hepatoprotective benefits in Brazilian patients with chronic hepatitis C even in lower daily consumption than in American and European populations.
    Machado SR; Parise ER; Carvalho Ld
    Braz J Infect Dis; 2014; 18(2):170-6. PubMed ID: 24275378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.
    Marventano S; Salomone F; Godos J; Pluchinotta F; Del Rio D; Mistretta A; Grosso G
    Clin Nutr; 2016 Dec; 35(6):1269-1281. PubMed ID: 27060021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Huang W; Zhang XX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of environmental factors in the etiology of hepatocellular carcinoma].
    Tornai I
    Orv Hetil; 2010 Jul; 151(28):1132-6. PubMed ID: 20570793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.